Now On-Line:

On June 30th, Dr. Edda Gomez-Panzani, a dear friend of NorCal CarciNET passed away from cancer. Edda gave several talks to our group over the years and was very supportive not only to our support community but to many support groups across the world. Edda was instrumental in the recent FDA approval for lanreotide late last year. To celebrate her life, we have put up a remembrance page on our web site. Please feel free to add your thoughts to the page.

LAcnets and Caring For Carcinoid Foundation held a patient education day in Los Angeles on June 27, 2015. Speakers included members of the Cedars-Sinai NETs team and invited guests from around the country to discuss immunotherapy and PRRT. Click here to view the videos.

On June 8, 2015, Josh Mailman, patient advocate, and president of the NorCal CarciNET Community, was honored with the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award. The award reads, "For substantial contributions to the SNMMI patient outreach program and leadership of the Patient Advocacy Advisory Board (PAAB)."  To read more about the award click here.

 

Advanced Accelerator Applications (AAA) filed a New Drug Application (NDA), with the FDA this month on Somakit - their Ga68 DotaTate imaging agent. They also announced a €23 million financing.

Chiasma raised $101.8 million in its initial public offering. Chiasma has completed a Phase 3 trial for a drug, oral octreotide, for the treatment of acromegaly. It submitted a new drug application on June 15 to the FDA, and already has orphan drug designation for acromegaly. As indicated in regulatory filings, Chiasma also plans to use some of the proceeds to pursue a Phase 3 trial in Europe for acromegaly, as well as starting a Phase 2 trial for treating neuroendocrine tumors.